INTRODUCTION

Clinical subtypes in breast cancer
Breast cancer is one of the highest leading causes of cancer death in the United States. About 12% of women will develop breast cancer over the course of their lifetime [1] . It is a heterogeneous disease with variety of subtypes that are classified by different histologies, levels of gene expression, disease aggressiveness, clinical outcomes, as well as genomic abnormalities [2] . Breast cancer can be classified into three clinical subtypes: estrogen receptor (ER+) or progesterone receptor (PR+) positive, human epidermal growth factor receptor 2 positive (HER2+), and triple negative (ER-/PR-/HER2-) disease [2] . ER+ and PR+ breast cancer overexpresses either the estrogen or progesterone receptors, and is found in 60-80% of breast cancer cases [3] . This type of cancer is more common in older patients, and generally has a better prognosis compared with the other subtypes. In addition, the ER+/PR+ subtype is associated with more differentiated and lower histological grade tumors, which may also play a significant role in the prognostic outcomes since lower grade tumors tend to grow and spread slower [4] . Furthermore, anti-endocrine therapies have been shown to be effective in treating ER+/PR+ breast cancer. For example, the drug tamoxifen− clinically used worldwide for more than 3 decades− is effective in treating many hormone receptor positive cancers because it is an anti-estrogen that blocks the binding of estrogen to ER [5, 6] .
HER2+ breast cancers are found in about 20% of patients and are associated with higher mortality rate, along with earlier disease relapse [3] . This more aggressive clinical subtype tends to have a less positive prognosis, partly due to the elevated proliferative and metastatic potential induced by HER2 [7] .
This has led to the development of drugs that specifically target the HER2 receptor, and aid in the treatment of HER2+ breast cancers. The FDA approved Trastuzumab in 1998, which led to the routine use of a clinical assay for HER2 positivity on all breast cancer cases [3] . Trastuzumab is a monoclonal antibody that binds the HER2 receptor and blocks its activation and downstream signaling to inhibit HER2-positive breast cancer cell growth and survival [1] . Some HER2+ breast cancers acquire resistance to Trastuzumab, which has led to the development of multiple approaches to targeting HER2. For example, in 2007 the FDA approved the use of Lapatinib [8] , a small molecule inhibitor of the kinase domain of HER2 (and the related epidermal growth factor receptor (EGFR)/HER1 receptor); and in 2012 another HER2 binding antibody, Pertuzumab [9] was also FDA approved for the treatment of HER2-positive breast cancers.
The ER-/PR-/HER2-, or triple negative subtype is associated with aggressive tumors, and this subtype occurs in about 15% of all breast cancer cases [3] . Triple negative breast cancer cells do not express any of the hormone receptors (ER, PR) nor HER2, which prevents their treatment by either ER or HER2 targeted therapies, leaving systemic chemotherapy as the only treatment option [7] . The DNA damage response mechanisms play important roles in many triple negative breast cancers, as the tumor suppressors p53, BRCA1, and BRCA2 are often mutated in this subtype. Research has shown that p53 is mutated in about 82% of triple negative cancers [3] . Additionally, BRCA1 or BRCA2 mutations occur in up to 10% of triple negative cancers, and women with either mutation are at a 45-75% lifetime risk of developing breast cancer in their lifetimes [10] . Increased mitogenic signaling may also drive the proliferation of some triple negative breast cancers. Recent studies carried out by the Cancer Genome Atlas indicate that PIC3CA, a gene encoding for an isoform of phosphoinositide 3 kinase (PI3K), is mutated in about 9% of triple negative breast cancers [11] . The triple negative subtype is also more common in younger patients, and in women of African descent. Tumors in these patients are often found poorly differentiated and higher grade, which further contributes to their poor prognosis [4] .
HER2 and the PI3Kinase/Akt/mTOR signaling pathways in breast cancer HER2, also known as ErbB2/neu, is a receptor tyrosine kinase (RTK), and is one of the four members of the epidermal-like growth factor family of receptors (EGFR). The other receptors of the EGFR family are EGFR/HER1, HER3, and HER4 [12] . All four of the transmembrane receptors can form homodimers and heterodimers, which can be enhanced by ligand binding. HER2 is referred to as an "orphan receptor" because unlike the other three it does not directly or singly interact with any known ligand. However, it dimerizes with other ligand-binding EGFR family members to modulate HER2 tyrosine kinase activity negatively or positively depending on the ligand/dimerization partner [13] . Upon dimerization, the HER2 receptor undergoes auto-or-trans-phosphorylation. As mentioned previously, the overexpressed and phosphorylated HER2 receptor activates the downstream phosphoinositide 3 kinase, protein kinase B (also known as AKT), mammalian target of rapamycin (PI3K/AKT/mTOR) pathways, which increase cell proliferation and survival [14] (Figure 1 ).
PI3Ks are part of a family of lipid kinases that phosphorylate phosphatidylinositol at the 3' hydroxyl group [15, 16] . The dysregulation of the PI3K pathway has been found in a variety of cancers [16] . The catalytic subunit of PI3K, p110α is involved in regulating cell proliferation, and plays an important role in tumorigenesis [17] . Gain-of-function mutations in p110α, specifically in its helical and kinase domains, are found in about 30% of tumors, including breast, and are associated with increased AKT signaling [17] . Wild type PI3K can be activated by RTKs, via adaptor proteins that sequester to its inhibitory subunit p85, thereby activating the p110 kinase domain [16] . Activated p110 phosphorylates PIP 2 , (phosphatidylinositol 4,5-biphosphate) thus producing PIP 3 (phophatidylnositol-3, 4,5 triphosphate), a lipid second messenger [18] . Conversely, PIP3 is negatively regulated via dephosphorylation by PTEN (phosphatase and tensin homolog) a tumor suppressor protein; however in many cancers, PTEN is inactivated or lost leading to increased levels of PIP 3 [16] . PIP 3, subsequently binds to PDK1 (3-phosphoinositide dependent protein kinase-1), which phosphorylates and activates AKT [16, [19] [20] [21] .
AKT is a serine/threonine kinase that controls protein synthesis and cell growth by phosphorylating mTOR (mammalian target of rapamycin) [19] . AKT has three isoforms, AKT 1/2/3, as well as at least two phosphorylation sites, S473 and T308. Phosphorylation on both sites increases the kinase activity and causes AKT to dissociate from the membrane, allowing it to activate the TORC1 complex and other downstream substrates [18] . mTOR is a serine/threonine kinase that regulates cell growth, proliferation, survival, and metabolism [22] . mTOR has two multi-protein complexes, mTORC1, and mTORC2. mTORC1 consists of mTOR, mLST8 (G-protein β-subunit-like protein) and raptor (regulatory associated protein of mTOR). This complex is involved in regulating cell growth, proliferation, survival, as well as nutrient and energy signals [23] . Furthermore, mTORC1 has been shown to phosphorylate p70 S6 kinase (S6K1), and eukaryotic initiation factor 4E-(eIF4E) binding protein 1 (4eBP1) [23] . In comparison, mTORC2 consists of mTOR, mLST8, and rictor (rapamycin-insensitive companion of mTOR). Unlike mTORC1, mTORC2 has been shown to regulate the actin cytoskeleton, and phosphorylates AKT on the S473 residue to modulate cell shape, motility, and invasive abilities [23] .
In mammals there are two ribosomal S6 kinases, S6K1 and S6K2, whose activation is regulated by mTOR [23] [24] [25] . A substrate of S6 kinases is the ribosomal protein S6, which is also referred to as RPS6. S6 controls cell growth by affecting mRNA translation and protein synthesis. mTOR activated S6K1 promotes translation and protein synthesis by phosphorylating the 40S ribosomal protein S6, as well as the translation initiation factor eIF4B [23] .
4eBP1, is another downstream target of mTOR, that acts as a repressor of eIF4E [23] . When 4eBP1 is hypo-phosphorylated, it binds to eIF4E and represses cap-dependent translation to prevent eIF4E from binding to eIF4G.
However, when 4eBP1 is phosphorylated by mTOR, it dissociates from eIF4E, which allows for different initiation factors including the 40S ribosomal subunit to be positioned at the 5' end of the mRNA to help start the scanning process of the mRNA [23] . Elevated levels of eIF4E have been found in a variety of cancers, including breast cancer [26] . Furthermore, overexpression of eIF4E has been shown to be tumorigenic by dysregulating translation of oncogenes [24] . Given this information, researchers have greatly focused on mTOR inhibition in order to identify new and more effective anticancer agents. mTOR inhibitors such as rapamycin-related rapalogs (e.g. FDA approved Everolimus and Temsirolimus), that inhibit TORC1, have been shown to reduce tumor angiogenesis, and have clinical anti-tumor activity [22] . However, they are unable to inhibit TORC2.
Studies have shown that inhibition of TORC1 alone up-regulates AKT phosphorylation which can lead to tumor progression. Specifically, activated S6K phosphorylates, and negatively regulates, insulin receptor substrate 1 (IRS-1), ultimately leading to decreased PI3K and AKT activity. Consequently, inhibition of TORC1 causes reduced S6K activity, and an increase AKT. However, inhibition of TORC2 decreases AKT activity. Thus, inhibiting both mTOR complexes could prevent activation of that feedback loop and result in improved therapeutic effects [23] .
Mammalian target of rapamycin inhibitors
Intellikine Inc. (recently acquired by Takeda/Millennium Pharmaceuticals) developed the selective TORC1/2 ATP site inhibitor MLN0128 (previously known as INK128). Unlike rapamycin and rapalogs that allosterically inhibit TORC1 and only weakly inhibit p4eBP1 levels, MLN0128 is able to decrease the phosphorylation of S6, and inhibit p4eBP1 levels [27] [28] [29] . MLN0128 also decreases AKT activity since it inhibits TORC2 as well ( Figure 1 ). MLN0128 has been shown to inhibit the proliferation of various subtypes of breast cancer cell lines with high potency and to potently inhibit growth in human breast cancer xenograft models [29] . Additional research demonstrated that MLN0128 can suppress the progression of leukemia, and may have therapeutic effects in treating B-cell acute lymphoblastic leukemia [30] .
Histone Deacetylases (HDACs) and their inhibition
Aside from the mutations in the PI3K/AKT/mTOR pathway, there are epigenetic mechanisms that commonly contribute to the development of breast and other cancers. Posttranslational modifications such as acetylation and methylation affect gene expression, and may contribute to cancer development [31] . Histone deacetylases (HDACs) remove acetyl groups from histones and various other non-histone proteins to modulate gene expression [31, 32] . For genes like the tumor suppressor p21, an increase in HDAC activity can repress its transcription. High expression of HDACs has been documented in many different cancers implicating its importance in the carcinogenesis process [32] .
Furthermore, a global pattern of histone hypoacetylation has been associated with malignant progression of breast cancer [33] . There are three classes of mammalian HDACs. Class I includes HDAC1, HDAC2, HDAC3, and HDAC8.
This class of HDACs are mainly localized in the nucleus [34] . Class II consists of HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10. This class of HDACs can move between the nucleus and the cytoplasm [34] . Class III HDACs− structurally unrelated to the class I or II HDACs− are composed of a family of NAD-dependent sirtuins (SIRs). The SIRs are unaffected by all of the class I or II HDAC inhibitors developed to date [34] . It is also interesting to note that higher expressions of HDAC4, HDAC8, and HDAC9 have been found in tumor tissues in comparison to normal tissues [34] .
Better understanding of HDACs and their role in tumorigenesis has fueled the development of HDAC inhibitors (HDACi's) as a new type of cancer therapeutic [34] . HDAC inhibitors prevent HDAC's from removing acetyl groups from histones and non-histone proteins and, therefore, can alter gene expression and reverse the diverse tumorigenic effects of increased HDAC activity [34] . While HDAC inhibitors have been shown to inhibit angiogenesis and metastasis in pre-clinical models, less is known about the mechanism of how they kill tumor cells while sparing normal cells [31] .
The currently available HDACi's− referred to as pan-HDACi− inhibit both class I and class II HDACs. In 2006, the first pan-HDACi inhibitor, Vorinostat was clinically approved for the treatment of cutaneous T cell lymphoma. In 2009, the FDA approved another such pan-HDACi, Romidepsin, for the same clinical indication [31] . Panobinostat and Entinostat are two newer HDACi's whose clinical development includes trials in patients with advanced stage breast cancer [31, 35] .
In addition to pan-HDACi, class-specific HDACi are also in preclinical and clinical development. For example, recent studies have shown that Entinostat, a class I HDAC inhibitor, is able to induce apoptosis in breast cancer cells, as well as down regulate HER2 and HER3 [35] . In addition, class II specific HDACi's such as MC1568 and MC1575 show anti-proliferative activity in human melanoma cells [36] , as well as in human breast cancer cells [37] .
This study focuses on a potent pan-HDAC inhibitor, Trichostatin-A (TSA), an antifungal antibiotic that acts as a reversible non-competitive inhibitor [38] .
TSA remains in preclinical studies and has been shown to promote cell cycle arrest in the G 1 and G 2 phases, and in some cases promote apoptosis. In some cancer cells, TSA has been shown to induce differentiation rather than promote cell death [38] . TSA (and other pan-HDACi's) has also been shown to induce HER2 mRNA degradation [39] . Furthermore, unpublished data from the Benz lab have shown that the addition of cyclohexamide to HER2 positive SKBR3 breast cancer cells inhibits polyribosome (polysome) formation and reverses the effects of TSA, suggesting that polysome function and active translation appear to be necessary for HDACi to promote HER2 mRNA degradation.
Research Goals
The focus of this project was to determine the therapeutic potential and anti-tumor mechanism of action of mTOR and HDAC inhibitors, represented by MLN0128 and TSA respectively, as individual anticancer agents and in therapeutic combination, and to determine if their potential utility is dependent on a specific breast cancer phenotype, be it hormone receptor (ER, PR)-positive, HER2-positive, or neither. Since breast cancer cell lines modeling these different breast cancer clinical phenotypes are readily available, we examined the effects of these inhibitors on breast cancer cell viability and determined how these phenotypically different model breast lines respond to MLN0128/TSA treatment given as single agents or in combination. To understand the antitumor mechanism(s) of these drugs with regard to phosphorylation events in the PI3K/AKT/mTOR signaling pathway, we determined if adding TSA to MLN0128 impairs or enhances activation of AKT, S6, and/or 4eBP1. Since unpublished data from the Benz lab also indicated that polysome function is necessary for TSA to induce HER2 mRNA decay, we further evaluated the possibility that mTOR inhibition could antagonize the anti-tumor effects of TSA by inhibiting polysome function. Furthermore, since HDACi's can impair cancer cell growth, we determined whether its growth inhibiting interaction with MLN0128 induces apoptosis in breast cancer cells relative to non-transformed MCF-10A cells.
MATERIALS AND METHODS
Cell Culture
Human breast cancer cells lines expressing different levels of ER/PR and HER2 levels were cultured under sterile conditions and incubated at 37°C in 5% Polysome profile analysis was employed as recently described [40] . A sucrose gradient was poured by layering 10%-50% sucrose buffers. Gradients were kept at room temperature for 1hr and 45 minutes to form continuous gradient, and placed in the -80°C until the day of polysome fractionation. On the day of fractionation, the samples were layered on top of the continuous sucrose gradient and the samples were spun at 38,000 rpm for 2 hours at 4°C. The gradients were fractioned and polysome fractions were then collected by utilizing the Retriever 500 with ISCO Teledyne UV/Vis (UA6). 
Apoptosis Assay
RESULTS
Combination of TORC1/2 and pan-HDAC inhibitors synergistically decreases breast cancer cell viability
To assess the effect of single agent and combination treatment using the TORC1/2 inhibitor, MLN0128, and the pan-HDACi TSA, we utilized the CellTiterGlo assay to measure cell viability in a variety of breast cancer cells (Figure 2 ).
IC 50 values for MLN0128 and TSA ranged from 4.64nM to 25nM, and 30.9nM 
TORC1/2 inhibitor blocks downstream signaling effectors
To examine the early effects of MLN0128 and TSA on the adding TSA at 100nM further decrease AKT phosphorylation ( Figure 5D , 5E, 5F).
To determine the effects of long-term treatment with MLN0128 and/or TSA on PI3K/mTOR/AKT pathway signaling events, we evaluated 24-hour treatments of both drugs as single agents, or in combination at varying concentrations of TSA (0nM, 50nM, and 1000nM) ( Figure 6 ). Although low doses of MLN0128 decreased the phosphorylation of S6 and 4eBP1, very high doses of TSA (1000nM) were necessary to block S6 and 4eBP1 phosphorylation. Furthermore, high doses of TSA in combination with MLN0128 further inhibited S6 and 4eBP1
phosphorylation when compared to either of the single agent treatments ( Figure   6 ), suggesting that both drugs are capable of modulating S6 and 4eBP1 phosphorylation with MLN0128 being more potent than TSA.
As previously mentioned, unpublished Benz Lab data shows that TSA promotes HER2 mRNA degradation in a polysome dependent manner. Since MLN0128 affects the phosphorylation of ribosomal proteins, including S6 ( Figure   5 ), we next examined whether MLN0128 can prevent TSA-mediated reduction in HER2 levels. Results in figure 7 indicate that HER2 protein levels were decreased following a 24-hour treatment with 1000nM of TSA even in the presence of MLN0128 (Figure 7 ). While TSA did not alter HER2 protein levels significantly within 24 hours of treatment, it did reduce pHER2 to a nondetectable level and blocked HER2 activation. MLN0128 did not appear to have any effect on HER2 activation or total HER2 levels in absence of TSA, nor did it appear to interfere with the effects of TSA on HER2 expression or phosphorylation ( Figure 7 ). The observed decrease in HER2 protein levels may be attributed to mRNA degradation; further testing will be necessary to examine the effects of TSA and MLN0128 on HER2 mRNA levels.
Inhibitors of TORC1/2 and HDACs decrease polysome formation
The PI3K/AKT/mTOR pathway is known to affect posttranslational modifications on ribosomal proteins and translation initiation factors [28] , Since sustained TSA reduced S6 phosphorylation after 24 hours of treatment ( Figure 6) we investigated the effects of MLN0128 and TSA on polysome formation and structure. We used a 50nM concentration of MLN0128 (10x the IC 50 value) and a 500nM of TSA (16x the IC 50 value). MLN0128 alone caused a subtle decrease in 
DISCUSSION
HER2 overexpression and phosphorylation, and the activation of the PI3K/Akt/mTOR pathway have been linked to increased breast cancer cell survival, growth, and metastasis [7, 16, 17] . HER2 amplification has been associated with very poor prognosis in breast cancer patients [7] with a variety of resistance mechanisms developing either de novo or soon after clinical treatment with HER2 targeted therapies. In this study, we tested the therapeutic potential of a potent and investigational mTORC1/2 inhibitor, MLN0128, as a stand-alone treatment and in combination with a pan-HDAC inhibitor, TSA. Studies were conducted to evaluate the effects of these drugs alone or in combination on cell viability, PI3K/Akt/mTOR signaling, and polysome formation.
Our data show that MLN0128 and TSA synergistically inhibit cell viability Figure 2G ). These results suggest that MLN0128 and TSA given in combination could exhibit antitumor activity in vivo without significant toxicity to non-malignant cells; however, this conclusion requires additional preclinical in vivo testing.
In addition to inhibiting cell viability, studies have shown that MLN0128 is effective in blocking mTORC1/2 signaling which promotes survival of cancer cells by regulating proliferation, growth, metabolism, invasiveness, and motility [22] .
More specifically, MLN0128 has been reported to inhibit pS6, p4eBP1, and pAKT-S473, in preclinical studies [27] [28] [29] [30] . In line with these studies, our results also indicate that MLN0128 inhibits phosphorylation of S6 and 4eBP1 ( Figure 5 ), both of which are downstream effector molecules of mTOR [23, 25] .
Furthermore, earlier studies have indicated that inhibition of mTORC1 alone may not be sufficient because mTORC1 inhibitors (rapalogs) have been shown to increase the phosphorylation of AKT on S473 [23, 29] . Consistent with this, data from this study also show that MLN0128 is able to inhibit AKT S473 phosphorylation. We also demonstrated that TSA in combination with MLN0128
further reduces the phosphorylation of AKT S473, even though, in most cell lines tested, TSA alone has little if any effect on pAKT-S473 after 8 hours of treatment ( Figure 5 ). Although TSA was not able to inhibit pS6 and p4eBP1 after 8 hours of treatment, at a longer time point and higher doses, TSA did reduce phosphorylation levels of S6 and 4eBP1 when used in combination with MLN0128 ( Figure 6 ). Taken together, these findings suggest that pS6 and p4eBP1 could serve as robust biomarkers for MLN0128 response, and that pAKT-S473 may serve as a response biomarker for the MLN0128 and TSA combination therapy.
Since polysome function contributes to HER2 protein expression and is necessary for TSA to induce HER2 mRNA decay, we examined the effects of hours. Whole cell lysates were collected and western blots were performed using protein specific antibodies. 
